〔Abstract〕 Objective To investigate the value of apatinib assisted third-line chemotherapy in the treatment of advanced gastric cancer. Methods A total of 62 patients with advanced gastric cancer admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2019 to January 2020 were selected, according to their different treatment methods, they were divided into a control group with 30 cases, and an observation group with 32 cases. The control group was treated with third-line chemotherapy, and the observation group was additionally treated with apatinib adjuvant therapy. The disease remission rate and serum tumor markers were compared between the two groups. Barthel index was used to evaluate the quality of life of patients in the two groups before and after treatment. The incidence of adverse reactions was compared between the two groups. Results After treatment, the remission rate of the observation group was higher than that of the control group, and the difference was statistically significant (P < 0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199 and CA125 in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). The scores of quality of life in the observation group was significantly higher than that of the control group, with statistical significance (P < 0.05). During treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Apatinib assisted third-line chemotherapy is effective in the treatment of advanced gastric cancer, which can lower the levels of tumor markers, and improve the patients’ quality of life, with a low incidence of adverse reactions.